160522-88-3 Usage
Uses
Used in Pharmaceutical Development:
2,4-bis[4-(4,5-dihydro-1H-imidazol-2-yl)phenyl]pyrimidine is used as a potential pharmaceutical candidate for [specific application reason] due to its unique molecular structure and the presence of the pyrimidine core and imidazole substituents, which may contribute to its biological activity.
Used in Biochemical Research:
In the field of biochemical research, 2,4-bis[4-(4,5-dihydro-1H-imidazol-2-yl)phenyl]pyrimidine is used as a subject of study for [specific research purpose], given its structural complexity and the possibility of exploring its interactions with biological systems or its potential as a molecular probe.
[Note: The specific application reasons and research purposes are not provided in the materials, so they are left as placeholders to be filled in with accurate information once it becomes available.]
Check Digit Verification of cas no
The CAS Registry Mumber 160522-88-3 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,6,0,5,2 and 2 respectively; the second part has 2 digits, 8 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 160522-88:
(8*1)+(7*6)+(6*0)+(5*5)+(4*2)+(3*2)+(2*8)+(1*8)=113
113 % 10 = 3
So 160522-88-3 is a valid CAS Registry Number.
InChI:InChI=1/C22H20N6/c1-3-16(20-24-11-12-25-20)4-2-15(1)19-9-10-23-22(28-19)18-7-5-17(6-8-18)21-26-13-14-27-21/h1-10H,11-14H2,(H,24,25)(H,26,27)
160522-88-3Relevant academic research and scientific papers
Anti-Pneumocystis carinii pneumonia activity of dicationic 2,4-diarylpyrimidines
Kumar,Boykin,Wilson,Jones,Bender,Dykstra,Hall,Tidwell
, p. 767 - 773 (2007/10/03)
A synthesis of 2,4-bis-(4-amidinophenyl)pyrimidine 6, 2,4-bis-[(4-imidazolin-2-yl)phenyl)]pyrimidine 7, 2,4-bis[(4-tetrahydropyrimidinyl-2-yl)phenyl]pyrimidine 8, 2,4-bis[(4-N-n-propylamidino)phenyl]pyrimidine 9, 2,4-bis[(4-N-isopropylamidino)phenyl]pyrimidine 10 and 2,4-bis[(4-N-isobutylamidino)phenyl]pyrimidine 11 starting from 4-bromobenzamidine and 4-bromoacetophenone is reported. A synthesis of 2-(4-amidinophenyl)-4-(2-methoxy-4-amidinophenyl)pyrimidine 20, 2-[4-(imidazolin-2-yl)- phenyl]-4-[2-methoxy-4-(imidazolin-2-yl)phenyl]pyrimidine 21, and 2-[4-(N-iso-propylamidino)phenyl]-4-[2-methoxy-4-(N -isopropylamidino)phenyl]pyrimidine 22 beginning with 4-bromobenzamidine and 2-methoxy-4-bromoacetophenone is described. Compounds 6-11 and 20-22 all bind strongly to DNA. Compounds 6, 9-11, and 20 given at 5 mg/kg are more active and less toxic than pentamidine at its effective dose when evaluated against Pneumocystis carinii pneumonia (PCP) in the immunosuppressed rat model. Several compounds in this series are being evaluated further as potential new anti-PCP agents.
